Last reviewed · How we verify

Remeron — Competitive Intelligence Brief

Remeron (mirtazapine) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: NaSSA (Noradrenergic and specific serotonergic antidepressant). Area: Neuroscience.

marketed NaSSA (Noradrenergic and specific serotonergic antidepressant) 5-hydroxytryptamine receptor 1A, 5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2C Neuroscience Small molecule Live · refreshed every 30 min

Target snapshot

Remeron (mirtazapine) — Generic (originally Organon/MSD). Noradrenergic and specific serotonergic antidepressant (NaSSA) that blocks alpha-2 adrenergic, 5-HT2, 5-HT3, and H1 receptors.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Remeron TARGET mirtazapine Generic (originally Organon/MSD) marketed NaSSA (Noradrenergic and specific serotonergic antidepressant) 5-hydroxytryptamine receptor 1A, 5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2C 1996-06-14

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (NaSSA (Noradrenergic and specific serotonergic antidepressant) class)

  1. Generic (originally Organon/MSD) · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Remeron — Competitive Intelligence Brief. https://druglandscape.com/ci/mirtazapine. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: